Ken Griffin Kronos Bio, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,300 shares of KRON stock, worth $9,021. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,300
Previous 31,400
70.38%
Holding current value
$9,021
Previous $38,000
76.32%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding KRON
# of Institutions
56Shares Held
19.8MCall Options Held
9.3KPut Options Held
100-
Vida Ventures Advisors, LLC2.77MShares$2.68 Million3.24% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$1.98 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.92MShares$1.87 Million0.0% of portfolio
-
Partners Capital Investment Group, LLP Boston, MA1.61MShares$1.56 Million0.03% of portfolio
-
Alphabet Inc. Mountain View, CA1.44MShares$1.4 Million0.1% of portfolio
About Kronos Bio, Inc.
- Ticker KRON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,769,100
- Market Cap $55.1M
- Description
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...